Ricci Whitlow, COO of MiMedx Group Inc (MDXG, Financial), sold 31,043 shares of the company on February 15, 2024, according to a recent SEC Filing. MiMedx Group Inc is a biopharmaceutical company that develops, manufactures, and markets regenerative biologics utilizing human placental tissue allografts for multiple sectors of healthcare.
Over the past year, the insider has sold a total of 31,043 shares and has not made any purchases of the stock.
The insider transaction history for MiMedx Group Inc shows a pattern of insider activity. In the past year, there have been 2 insider buys and 22 insider sells.
On the valuation front, MiMedx Group Inc's shares were trading at $8.05 on the day of the insider's recent transaction. The company has a market cap of $1.180 billion.
The stock's price-to-GF-Value ratio stands at 1.2, indicating that it is modestly overvalued in comparison to the GF Value of $6.71.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
